Informa Pharma Intelligence has announced Citeline Engage, a new solution allowing contact research organizations (CROs) and sponsors to optimize site selection and increase trial efficiencies to accelerate clinical trial timelines and enable a faster path to market for drugs. Citeline Engage is a solution designed specifically to help optimize protocol development, site feasibility, and most importantly, increase physician engagement and drive patient awareness to support faster enrollment into clinical trials.
Clinical trials have long been a pain point for industry players, and Citeline Engage is designed to help increase efficiency across a notoriously difficult, yet imperative area, of the pharma industry. Informa Pharma Intelligence’s Citeline Engage utilizes real-world data to offer the most efficient outreach services that allow customers to better recruit investigators and patients, optimize trial protocols, and ignite awareness around trials.
By combining trial and investigator intelligence available through Citeline with a verified audience of healthcare professionals through Skipta, Citeline Engage helps CROs and sponsors expedite patient enrollment, drive efficiency and mitigate the risk of trial failure:
“We have the real-world data to create powerful connections and optimize protocol development, site feasibility, and most importantly physician engagement and patient awareness,” said Nicola Marlin, Vice President of Product Development at Informa Pharma Intelligence. “Citeline Engage empowers organizations to create and run the most efficient clinical trials possible through targeting and recruiting top tier investigators and select sites using online communities of verified healthcare professionals.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.